Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose

Bibliography

• de Lange EC, Danhof M. Considerations in the use of CSF pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703
   PubMed Web of Science ®Google Scholar
• Read KD, Braggio S. Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 2010;6(9):337-44
   PubMedGoogle Scholar
• Braggio S, Montanari D, Rossi T, Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 2010;5(7):609-18
   PubMed Web of Science ®Google Scholar
• Smith DA, Schmid EF. Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006;9(1):38-46
   PubMed Web of Science ®Google Scholar
• Li D, Kerns EH. Application of pharmaceutical profiling assays for optimization of druglike properties. Curr Opin Drug Discov Devel 2005;8:495-504
   PubMed Web of Science ®Google Scholar
• Peck RW. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. DDT 2006;12:289-94
   Web of Science ®Google Scholar
• Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001;41:856-64
   PubMedGoogle Scholar
• Lipinski CA, Lombardo F, Dominy BW, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Teague SJ, Davis AM, Leeson PD, The design of leadlike combinatorial libraries. Angew Chem Int Ed 1999;38:3743-8
   PubMed Web of Science ®Google Scholar
• Leeson PD. Davis AM, Steele J. Drug-like properties: guiding principles for design – or chemical prejudice? DDT 2004;1:189-95
   Google Scholar
• Lajiness MS, Vieth M, Erickson J. Molecular properties that influence oral drug-like behaviour. Curr Opin Drug Discov Devel 2004;7:470-7
   PubMed Web of Science ®Google Scholar
• Hann MM, Oprea TI. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004;8:255-63
   PubMed Web of Science ®Google Scholar
• Li D, Kerns EH. Biological assay challenges from compound solubility: strategies for bioassay optimization. DDT 2006;11:446-51
   PubMed Web of Science ®Google Scholar
• Wunberg T, Hendrix M, Hillisch A, Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. DDT 2006;11:175-80
   PubMed Web of Science ®Google Scholar
• De Witte RS. Avoiding physicochemical artefacts in early ADME–Tox experiments. DDT 2006;11:855-9
   PubMed Web of Science ®Google Scholar
• Leeson P, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Perola E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem 2010;53:2896-997
   Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;3:203-14
   Google Scholar
• Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008;51:817-34
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Hersey A, Montanari D, Probing the link between efficacy, ADMET and physic-chemical parameter space. Nat Rev Drug Discov 2011;10:197-207
   PubMed Web of Science ®Google Scholar
• Grimwood S, Hartig PR. Target site occupancy: emerging generalisation from clinical and preclinical studies. Pharmacol Ther 2009;122:281-301
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6
   PubMed Web of Science ®Google Scholar
• Smith DA, Li D, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 2010;9:929-39
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR. Ligand efficiency: a useful metric for lead optimisation. Drug Disc Today 2004;9:430-1
   PubMed Web of Science ®Google Scholar
• Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts fro drug discovery. Drug Discov Today 2005;10:464-9
   PubMed Web of Science ®Google Scholar
• Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-12
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
   PubMed Web of Science ®Google Scholar
• Statistica 8.0. Statsoft, Inc. 2300 East Tulsa, OK74104, USA. Available from www.statsoft.com
   Google Scholar
• JMP 6.0, JMP Europe, SAS Institute, Henley Road, Medmenham, Marlow, SL7 2EB UK. Available from http://www.jmp.com
   Google Scholar